AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
BioNTech Completes Minimum Acceptance Criteria for CureVac Share Exchange Offer
ByAinvest
Wednesday, Dec 3, 2025 9:03 am ET1min read
BioNTech has fulfilled the minimum acceptance requirements for the exchange offer for CureVac shares, with 184.071.410 CureVac shares, or 81.74% of the outstanding shares, tendered before the original offer deadline. The offer's acceptance period has begun and will end on December 18, 2025. Non-tendering CureVac shareholders will receive BioNTech ADSs or bar exchange payments after the completion of the post-offer reorganization, which may be subject to Dutch dividend withholding tax.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet